Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Authors:
- H. Cody MeissnerHMH. Cody Meissner
- Sarah S. LongSLSarah S. Long
- 1 December 2003
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 112 (6) , 1447-1452
Abstract
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe respiratory syncytial virus (RSV) infections in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This report summarizes the clinical trial information on which the guidance in the accompanying policy statement for administering RSV prophylaxis to certain children with a history of preterm birth, chronic lung disease, or congenital heart disease is based. On the basis of results of a recently completed clinical trial, palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks’ gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present.Keywords
This publication has 19 references indexed in Scilit:
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus seasonThe Pediatric Infectious Disease Journal, 2000
- Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulinArchives of Disease in Childhood, 2000
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseThe Journal of Pediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1998
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Respiratory syncytial virus–enriched globulin for the prevention of acute otitis media in high-risk childrenThe Journal of Pediatrics, 1996